UNIONDALE, N.Y.--(BUSINESS WIRE)--Angion Biomedica Corp. announced today that it will present Phase 2 data from one clinical program and three preclinical programs at the American Society of Nephrology Kidney Week, November 3-8, 2015 in San Diego, CA.
Two presentations are scheduled on Angion’s clinical stage investigational drug BB3, a proprietary small molecule with hepatocyte growth factor (HGF)-like therapeutic activities. In a presentation entitled “BB3, a Hepatocyte Growth Factor-like Small Molecule, Improves Outcome in Kidney Transplant Recipients with Delayed Graft Function," data from an interim analysis of a double-blind, placebo-controlled, multicenter Phase 2 study showed that BB3, administered as late as 24 hours after renal transplantation, met the primary and secondary endpoints of the study and improved outcome in patients with delayed graft function (DGF). BB3 has Orphan Drug and Fast Track designations from FDA, and is proceeding into Phase 3 in renal transplant patients with DGF in Angion’s GIFT (Graft Improvement Following Transplant) trial.
The effects of BB3 on renal function in transplant patients in the Phase 2 study parallels that seen in experimental models of kidney injury treated with BB3. These data will be the subject of an oral presentation entitled “Therapeutic Effects of BB3, a Small Molecule Hepatocyte Growth Factor Mimetic, in Kidney Reperfusion Injury.” BB3 exhibits anti-apoptotic and regenerative properties in vitro and in vivo and has efficacy in multiple preclinical models of injury in the kidney and other major organs. BB3 is entering a Phase 2 study on acute kidney injury in at-risk patients who are undergoing cardiac surgery (Angion’s GUARD study, Guard Against Renal Damage).
In addition, Angion will give presentations on two other compounds in its pipeline. Data on Angion’s novel anti-fibrotic compound ANG3070 in polycystic kidney disease will be presented in “Therapeutic Effects of the Fibrokinase Inhibitor ANG3070 in Polycystic Kidney Disease.” Angion’s novel compound ANG3586 for chronic kidney disease is the topic of “Identification of a New Aldosterone Synthase Inhibitor with Anti-Fibrotic Activity in Animal Models.” These compounds are Angion’s proprietary small molecules on track for IND submissions in 2016.
“We are excited to share our clinical and preclinical programs at a major nephrology conference. Our clinical data on BB3 correlate very well with the preclinical results and support our hypothesis that BB3 should reduce the severity of DGF and acute kidney injuries even when administered 24 hours after transplantation. We eagerly anticipate starting enrollment of the Phase 3 DGF study and the Phase 2 study in AKI, as well as advancing our preclinical leads to the IND stage,” said Itzhak D. Goldberg M.D., FACR, President and CEO of Angion.
About Angion Biomedica Corp.
Angion Biomedica Corp. is a biopharmaceutical company founded in 1998 focused on discovery and development of drugs that harness the body’s protective, reparative and regenerative systems for therapeutic benefit. Please obtain further information at www.angion.com, or contact us at mail@angion.com.
